Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: bobsson, 26 Apr 2024 16:07
Last post: DSFLAT, 12 Jun 2024 14:50
THERACRYF PLC will be holding the meeting Research and Development Update tomorrow at 13th Jun 2024 at 9:30am BST.
Investor Meet Company
STALICLA publishes on identification of first autism subgroup and matching treatment
Geneva, Switzerland, May 8, 2024 – STALICLA SA, a Swiss neuro precision biotech company, has provided proof-of-concept clinical data for DEPI (Databased Endophenotyping Patient Identification), its neuro precision discovery platform, enabling the identification of biological subgroups of patients with Autism Spectrum Disorder (ASD) and matching treatments, in a study published last week in Biomedicines
https://stalicla.com/media/news/stalicla-publishes-on-first-precision-medicine-study
Https://www.mdpi.com/2227-9059/12/5/991
Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage drug development company.
The Company is focused on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases.
Its core technology is Sulforadex, which is a method for synthesizing and stabilizing the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.
Its asset, SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive metastatic breast cancer. SFX-01 exploits sulforaphane's activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases.
Its pipeline includes breast cancer, glioblastoma, hematological malignancies, and analogues. It also has a licensing in neurodevelopmental disorders and schizophrenia.
MSM money
Well that transfer went smoothly, ...... not.
Started: scoredagainsteps, 22 Apr 2024 18:08
Last post: Nolupus, 24 Apr 2024 11:16
Bojo2020
Good to see you posting here :-)
All the best to you , and patience IS the Key here as usual ..
Yes and Scancell
Any connection with oxford bio/dyn
Started: bobsson, 22 Apr 2024 10:17
Last post: BOJO2020, 24 Apr 2024 10:11
Looks like Vulpes were holding shares in Chronus as a private company which have now translated to an Evgen holding. There may or may not have been some additional buying.
Sorry, but it is buttons to them (and not that big a figure even for a HNWI, let alone an ii) - and look at, and compare with, the high quality names that joined the 8p raise in the past.
Who according to a number of posters back then, must have known something/done their dd before participating etc etc.
Not saying that it is 100% certain that their investment is going to go the same way as Octopus and Mr Kight's for example, and good luck to you, but IMO, I would not get too excited by these recent holder updates.
This is promising. An investment company isn’t going to buy 20m shares if they are no wiser than us about the prospects in the company. Looks like they have invested £150k in EVG shares. I’m optimistic something is going to happen here soon.
Stephen Diggle is the Founder and CEO of Vulpes Investment Management, a family office-backed investment manager. Let me provide you with more details about his background:
Stephen Diggle has been working in finance since 1986.
He spent 15 years working at international investment banks in London, Sydney, and Hong Kong.
He was one of the two founders of Artradis Fund Management, a Singapore-based hedge fund company that launched in 2002 with US$4 million and peaked at nearly US$5 billion late in 2008.
Artradis was multi-award-winning and, for some time, the largest and most successful hedge fund in Asia, making US$2.7 billion for investors between 2002 and 2009, especially during the financial crisis of 2008.
Following the success of Artradis, Stephen founded Vulpes Investment Management in 2011. Vulpes is a diversified family office-led investment company that runs a diverse portfolio of assets.
Vulpes has been an early investor in companies such as Scancell and Oxford Biomedica, providing capital at critical times to keep these companies afloat.
Stephen holds a Master’s degree from the University of Oxford in Philosophy, Politics, and Economics1.
Stephen Diggle’s expertise in finance and his passion for finding undervalued biotech firms make him a significant player in the investment world.
vulpesinvest.com
bing.com
4
pilgrimammunition.com
5
pitchbook.com
What other companies has Vulpes invested in?
Tell me more about Artradis Fund Management.
How can I contact Stephen Diggle?
Chats
Plug-ins
Copilot GPTs
Copilot
Copilot
Designer
Designer
Vacation planner
Vacation planner
Cooking assistant
Cooking assistant
Fitness trainer
Fitness trainer
Recents
Stephen Diggle: Vulpes CEO and Investment Expert
Write about flavors and tastes or a favorite spice of yours
Yesterday
UK Companies Developing Sepsis Diagnostic Tests
2 days ago
Response stopped
New topic
Give us an update on the dispute notice issued to Stalicla.
Started: CJ39, 19 Apr 2024 08:36
Last post: CJ39, 21 Apr 2024 12:41
Yes, if the Stalicla deal is ok then this is a great buy in price. When I originally bought in after the Stalicla deal was announced, 200,000 shares cost around £9k -£10k. You can now get 200,000 shares for £1600. Maybe I’ll lose most of this but if EVG announces they have received the $500k plus expect the other $5m before the end of the year this increases 300% from here. If Stalicla make an offer for EVG you’d like to think they’ll have to pay £20m+ which is around 5p a share and a 600% increase. Of course if EVG announce the Stalicla deal is over then this plummets yet further.
@ CJ39
I think you are correct Stalica if you read their research there is a great unmet need for neurological drugs for conditions such as ASD Trials of recently tested drugs have failed to meet their endpoints with “The one size fits all approach “and a stratification approach is required for investigation with novel drugs This is where I think Stalica are desperate to get Evgen but on cheap !
It’s now ten weeks since the dispute notice was issued. What on earth is going on here? You would think that this would be resolved in a phone call, have we fulfilled our commitments for the $500k milestone payment or not? If not what have we not done?
The good news is that Stalicla have not pulled the plug.
I’m starting to think that Stalicla are reluctant to pay any money as they want to buy out EVG, it would save them a fortune compared to the $160m milestone payments plus royalties. Could that be why EVG acquired a new company and raised cash in order to show Stalicla that they won’t be pushed about and EVG are in no hurry to sell cheaply? Is it why we’ve finally seen some of the board finally buy some shares? It feels like Stalicla paid the original $500k to test out SFX-01 and then make a decision to scrap the deal or buy out EVG.
The above could be totally wrong but it is possible. It’s risky buying in here but I’m going to buy back in, only a few hundred thousand shares. I’m not encouraging anyone else to do the same, but just thought I’d share my views.
Started: xxProInvestorxx, 16 Apr 2024 09:16
Last post: xxProInvestorxx, 17 Apr 2024 10:51
I would agree that the Stalicla deal is still extremely important, particularly for the short term, however I do not agree that if the deal was pulled it would be game over. With the cash available from the raise, Evgen would still have time to complete on another deal. However, Stalicla pulling out would put significant pressure on not only the share price, but also management. The lack of any deals subsequent to Stalicla would raise concerns around the likelihood of another one being competed in time before cash runs out.
I do have to agree that it seems like Stalicla wanted SFX-01 on the cheap, a feeling I had when the news first dropped of the dispute, but maybe we're being too cynical and there really is something that Stalicla believe Evgen has missed to receive the payment. And if this was the reason for the slow payment from Stalicla, I would imagine that they will now rethink as the possibility of getting SFX-01 on the cheap has passed for now. With enough cash for circa two years, administration is off the cards for now and I doubt the majority of investors would support a lowball take-over bid. An offer of a least 5p may get support, but if management are confident in their ability to ‘add shareholder value’ over the next few years, than they may not recommend such an offer to shareholders.
I do not, however, agree that losing the Stalicla deal would benefit Evgen, such beliefs, in my opinion, are fanciful at best. The Stalicla deal is only for indications in neurodevelopmental disorders and so does not limit the ability to licence SFX-01 for other indications. Throughout the rest of the year I would like to see the Stalicla issues resolved and another deal completed on for confidence to return.
It’s a fair write up xxxinvestorxxx. It is a fair balanced view you’ve given and I can understand you wanting to be positive and optimistic.
I do agree with LWHL that everything does rest on the Stalicla deal, if that was to fall through then this is worthless and the fact there is some problem is alarming. On a positive note it’s almost 10 weeks since the dispute was issued and Stalicla haven’t pulled the plug but god knows what is going on. I am of the impression that Stalicla have a deal in place costing $160m plus royalties but have realised EVG is worth peanuts and why not try and pick up EVG for next to nothing if the SFX-01 is effective and save an absolute fortune. Maybe that’s why they are not paying the $500k and delaying moving this into phase 2?
That certainly is a splendid phrase, although I reckon that you would do well to get yourself a tin foil hat here...find someone to swap for your rose tinted glasses if you can....and put that saved money into a stock worthy of investment :)
Gallows joking aside - good luck to you and your fellow longs. If a miracle happens, at least I might be able to take a smaller loss on my rump holding left here.
Maybe the Stalicla deal raised some interest from other Bigger Pharma ?
Perhaps Stalicla pulling out would actually enable a bigger better deal to land on the table
Tin foil hat and rose tinted glasses in full effect ;-)
Thank you for sharing your detailed thoughts, xx, but unless Stal come up with the cash in full and assurances that the prior agreement will also be honoured in the event of further successful progress, then all the other stuff, including Chronos, is simply noise, IMO.
If anything, this recent stuff underpins the theory that this is a fully fledged lifestyle company and nothing more.
The tiny inside buys - when we have not even seen any large inside buys in the past either - and at a 1p price no less - is a joke. Sorry, but I just do not buy it. And nor does the market, by and large, it seems.
If Chronos really was worth many multiples of what they paid for it right now, then why would the directors not have loaded up? It would be an absolute no-brainer to do so, surely?!
Take into consideration their longer term track record here as well, the Juv debacle, a number of other questionable statements made here and there in interviews over the past couple of years (and more)...well, IMO there are far better punts out there right now, let alone investments, which this one cannot in any credible sense be called. GLA nevertheless.
Started: bobsson, 8 Apr 2024 16:59
Last post: LWHL, 13 Apr 2024 14:23
I remember people saying exactly the same thing when JK first became a TR-1, and then again when he further added to become the largest shareholder here.
Since allowed his position to be diluted, rather than participate in this latest raise, of course, and not the only one so far either.
But you raise a good point. It seems that, on the rare occasions when such outfits actually and finally look like they may be about to be worth something, rather than basically nothing...they will screw their smaller shareholders anyway.
Three-card monte feels like less of a hustle :)
Why has William Black bought 4M cheap shares in our little pharma company ?He must know something , a quick buck or exciting potential drug development ? Hopefully not eventual privatisation like my other investments like REDX & ETX
I'm with you on that DSFLAT.
TR1s stacking up nicely. None of them mine.
Stalicla maybe decided to play hardball, but the new partners will be ready to pick up from them, if they walk away.
I bought on the first news of the Stalicla deal and have been averaging all the way down since lol
Obviously hoping for some positive news from Stalicla
Sounds promising DSFLAT - have you been a buyer recently, as one million shares might have cost you a fair bit a year or so ago.
I am tempted to buy a few more, as I reseached Stalicla and they do seem to say they are progressing but evauating.
Started: CJ39, 5 Apr 2024 12:26
Last post: flashgarden, 11 Apr 2024 18:35
Thats the problem with companies like this. They forget that they do not exist to make tablets. They exist to make money.
I am completely with you with the name change. Chosen by a pharmacist not a businessman.
CJ39
“ It’s just been a disastrous 18 months since the Stalicla deal was announced. I’d like to hear from posters like xxxInvestorxxx, K3VMC, Trickymatters, Mozax for their take on things. I know we’ve not always agreed but they were all very civil and reasonable.”
Sorry, I’ve only just spotted this post.
I really like the Chronos acquisition.
“ Acquisition of Chronos Therapeutics, which features a neuropsychiatry portfolio including two assets developed to late pre-clinical stage and which sits within a resurgent area for Big Pharma, for £899,481 up front, and up to £2.5m in milestone payments, all in Evgen shares.”
Quite apart from the late stage products brought in with Chronos, they now have their neuropsychiatry experience and contacts. Since Stalicla may have decided to play hardball with EVG, they have the backup of taking sfx01 back off them and developing it through TheraCryf.
Clearly, whoever saddled them with “TheraCryf” a) thought they were being frightfully clever and b) has never been gifted a copy of “Marketing for Dummies”. Thankfully, their success will not depend on anything other than sfx001 efficacy in one or more of the many research projects going on. They are all worthy projects, but I think the gliablastoma research will get some additional prominence, due to President Biden’s interest in that field.
I added on the acquisition news, but I anticipated the subsequent slide - no stocks seem capable of sustaining any rise in this market. I added again today, so managed to get my average to 2.18p. If they have any commercial success at all, the first 3x should be an easy reach, but long term it could be stunning. If and could. Just my opinion.
I’ll be adding, gently.
It’s just been a disastrous 18 months since the Stalicla deal was announced. I’d like to hear from posters like xxxInvestorxxx, K3VMC, Trickymatters, Mozax for their take on things. I know we’ve not always agreed but they were all very civil and reasonable.
Hope you all had a nice Easter break. Surprised to see that anyone took up the raise offer.
Equally surprised to see inside buying, although then again, it was buttons really, so not surprised in that sense. Hardly the kind of investment sizes that inspire confidence, especially given the salaries, lack of prior inside buying etc. Rubbish deal for existing holders, naturally. Part and parcel for AIM, along with the lack of consequences for BOD failure.
Also looks like the biggest holder has come to similar conclusions to some of us. GLA.
Started: bobsson, 11 Apr 2024 16:06
Last post: bobsson, 11 Apr 2024 16:06
Is this a private investor buying in for a 4% stake?
Started: formerlyeasyp, 4 Apr 2024 07:54
Last post: Showjumper, 4 Apr 2024 09:50
At just 0.78 a little toe in the water once again, as soon there might be news about the delayed receipt, which hopefully will be positive.
All depends on the Stalicla deal. If it goes into phase 2 and EVG get the $5.5m milestone payments they have said they will get then things will look up. But god knows what is going on with that.
Agreed £51k is laughable but hardly surprising when you can buy on the open market cheaper than the offer.
On the plus side, "Dr Susan Foden (Chair), Dr Huw Jones (CEO) and Toni Hänninen (CFO) have agreed to subscribe for, in aggregate, 5,600,000 new Ordinary Shares (the "Subscription Shares") at the Issue Price (the "Subscription"). In addition to the Subscription as noted above, certain other PDMRs including Dr Helen Kuhlman (CBO) have subscribed for 3,000,000 new Ordinary Shares in aggregate via the Placing", so they have some faith.
Also, they have managed to place 79,400,000 shares to buy Chronos, presuming some due diligence was completed prior to agreeing to the deal they must also have faith in EVG.
I'm thinking of averaging down at this price, 20% below the placing.
Time will tell if this is sensible or not....
Yes it really is embarrassing, shows just how little confidence there is about Evgen. It really has been a disaster these last 18 months. Why are they not updating us about the Stalicla deal and payment dispute? It’s 8 weeks now, it’s ridiculous how they treat shareholders, they see shareholders as something brown that they’ve trodden in. Shareholders are an inconvenience to them that is for sure.
The share sale raised £51k.....
Laughably small amount of money imo. Cannot see EVG as being a going concern anymore. Open to listening to counter arguments.
Started: CJ39, 26 Mar 2024 12:52
Last post: CJ39, 4 Apr 2024 09:17
0.72p to sell now. The likes of Radar, Kingalf and I got a lot of criticism and called trolls for our negativity of this share. I hope some people will at least recognise we were just giving our realistic thoughts on the share. We’ve had a share dilution at 1p which we predicted, I seem to remember being told I was talking nonsense for that.
Showjumper, you were brave to buy back in . My hope is that you don't get stuck on the high jump you have taken, good luck.
I have bought back in. Lucky that I exited before and only lost fees but at under 1p I will sit on the couple of thousand pounds worth that I have purchased. I may add after the meeting.
Stalicla have a LOT of experts that spent 7 years and $100 Million before choosing Evgens SFX-01 and signing a $160M plus deal...
Give them time to evaluate the data and stop being a bunch of limp wristed knob heads ffs
IMO, the management have pretty much run out of road.
Enough cash to feed themselves and have a few research jollies for a bit longer, if the main shareholders are willing to tolerate it, but as an investment case, this brings absolutely nothing to the table now, IMO.
Started: CJ39, 25 Mar 2024 21:59
Last post: CJ39, 25 Mar 2024 21:59
Not lost much this time. I bought in for 1p after the dispute notice was issued and made a 10% loss. I was really confident that this would be quickly resolved, the $500k milestone payment would be received (as EVG have said that they have fulfilled their obligations) and we would get confirmation that this would go into phase 2 this year (as advised on Stalicla website at the time the dispute was issued) which would mean EVG would receive $5m in the coming months. I really believed that would happen.
But unfortunately something doesn’t seem right yet again. It’s getting on for 7 weeks since the dispute was issued and still no updates. No mention in last week’s presentation but fair enough, why should shareholders be kept up to date with important issues. The placing last week seems to confirms EVG know that the $5m to be received once the Stalicla deal goes into phase 2 is not going to happen any time soon because why dilute the shares yet again if there is no need?
What is going on here? The Stalicla deal is supposed to be worth $163m plus royalties and yet after receiving only $500k there are disputes and continued delays to expected payments.
I’m starting to think this Stalicla deal is going to fall through and if it does what are EVG left with? I wish that Stalicla deal had never happened, it made a lot of us buy in believing there would be an income stream which would bankroll the company.
Started: CJ39, 23 Mar 2024 07:21
Last post: LWHL, 24 Mar 2024 16:35
I am not sure if that MSN site is entirely reliable either, but regardless, I stand by my previous comment.
Presumably we will see some updates once the funding/dilution deal kicks in anyway. With, I expect, all of those ii's showing a reduction (diluted) in their holding here, if not some who have finally decided to update the market with their total exit, perhaps.
The 8p funding arrangement roster of new and existing participants kept me in this one, at a point when I was starting to reconsider. Having been a holder, most unfortunately, since the 18p days I think, with genuine LTH patience and investor mentality.
Not a mistake I will ever make with such outfits in future. Quick trades now and again on certain euphoric moments, sure. Investing? Nope.
You see plenty of posters lamenting and castigating the short term mentality of 'rainbow chasers', incapable of holding for more than short periods.
When it comes to AIM stocks, it is almost always the investor, not the trader, who turns out to be the fool.
The only longer term winners are the lifestyle directors in these types of outfits.
I wonder if the major shareholder register will ever be updated again? I find it inconceivable that it remains the same as before, going back to the 8p days. Hey ho.
There are some discrepancies when comparing the Evgen website and MSN
https://www.msn.com/en-gb/money/watchlist?ocid=msedgntp&cvid=d8c26ac081774cc79d07c5526c0a17af¬i=Price_Decrease&id=ao8f77&l3=L3_Ownership&investorId=all
https://evgen.com/investors/
Can’t find fault with any of that LWHL. When I bought in on the Stalicla news in Nov 2022 I really thought this looked an amazing investment, one which I would double, treble or quadruple my money on. I should have known it was another AIM share that looked promising but would end up a disaster. I don’t think I’ve ever seen a golden AIM share that was successful. They all seem to be a way for those involved to make good salaries with no personal risk.
I think you hit the nail on the head with stating that SFX-01 is years off being commercialised whilst any company doing a deal with EVG for SFX-01 would take years doing trials on the drug. Evgen do not have the time or money for that.
Evgen were incorporated in 2014, what have they been doing for 10 years to have one drug and for it to still be so far away from being used in any way?
I’m fed up of how those running Evgen see shareholders as something they have trodden in. They lied about they couldn’t buy shares, they never told us why Juvenesense pulled the plug, they never explained why the $5.5m to be received by Stalicla in 2023 changed, they aren’t giving us any information about the Stalicla dispute. What a huge disappointment Evgen have been.
This one would not pass my sniff test now. Even before the latest RNS.
Shame I applied different (less stringent) criteria to my stock market investments a few years ago.
I would have saved quite a lot of money by avoiding this one altogether. Barge-pole territory, through and through.
Finally some inside buying, although not nearly enough, and accompanied by the typical AIM dilution/soaking.
IMO, this is clearly an act of desperation to keep the salaries coming in for a bit longer. I think you cover the key realities in your post, CJ39.
The odd small spike here and there could still happen - this is AIM after all - but I think this is highly, highly, likely to go bust at some point. If their pipeline was any value whatsoever, it would have made better progress by now, as far as I am concerned. The BOD would have also bought in big and long before now, which is perhaps the biggest clue of them all.
And even if by some miracle they ever do get to a point where one of the products reaches commercialisation-ready stage, they will have made it virtually impossible for ordinary shareholders to benefit much, if at all, anyway.
STX comes to mind on that front.
I wonder if the major shareholder register will ever be updated again? I find it inconceivable that it remains the same as before, going back to the 8p days. Hey ho.
Ah well, GLA and good weekend all too.
We have now passed six weeks since the dispute to Stalicla was issued and still no news on what is happening with the deal. There was no mention of it in this week’s presentation.
This week EVG issued a placing of shares, if I’ve read right they have issued a placing of shares that has diluted the shares by almost 50% which makes it far harder for shareholders to get their money back. Why would you issue a share placing diluting the shares if you are expecting $5.5m this year from Stalicla? It’s as if they know that money is not coming this year now.
This is becoming a mess IMO. Once a company starts shifting focus elsewhere from what their main operations it’s a sign that it’s game over.
It’s been a terribly disappointing last 12 months for EVG. No new deals signed whatsoever despite EVG trying hard to do so. Huw was out in California trying to network and EVG were present at events trying to drum up interest from other pharmas, but all to no avail.
Evgen lost the Juvenesense deal which was going to be a vital income stream. The $5.5m to be received by end of 2023 changed to expected up to $5.5m in 2024 but that is now looking less likely since Stalicla removed that this would go into phase 2 this year. Add to that the cash reserves have been falling from having decent funds in 2022 to running out this year. And now we have a share placing that many of us feared would happen.
What looked like an amazing investment opportunity now looks a sorry mess.
Started: davey50, 19 Mar 2024 17:34
Last post: DSFLAT, 24 Mar 2024 08:43
The BOD have just invested about 10% of the placing...
It sounds like Chronos investors have invested and perhaps Mr J. R. Kight has also taken more shares and was waiting for the placing...
The Stalicla deal is still on the table and Evgen may have just made themselves a future target for acquisition.
EVGEN PHARMA PLC - Investor Presentation
53 views 1 day ago
https://youtu.be/_H0xBzEyJMw?si=8mee0VASv1I4gBUQ
chronoscreen™ presentation was either swerved because it could be a threat to stalicla and firefly diagnostics and 'the deal'
or chronoscreen™ is a bag of ****e not worthy of mention ....
After the investor presentation I gave feedback that there could have been some mention of Chronoscreen™
"Chronos dedicated laboratory in Oxford which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen™ "
Bring up Chronoscreen™ and talk about how it works and maybe sprinkle with some planned AI integration and it might raise investor interest...
Just my thunking
I think this acquisition has been on the cards for a while.
Maybe since HUW resigned his directorship.
It could also explain HUW's claim that he was unable to purchase shares.
Maybe they were hoping to have the stalicla money by now and have had to restructure the deal.
Dont think this undermines any deal with stalicla because that relates to sfx01 only and is associated quite specifically with neurodevelopmental disorders.
I hate the new name and often associate name changes with desperation.
Started: DSFLAT, 22 Mar 2024 09:10
Last post: DSFLAT, 22 Mar 2024 09:10
Prof Popat says the use of blood tests or 'liquid biopsies' is likely to broaden to breast cancer and cancers in children.
https://www.bbc.co.uk/news/health-68624334
The tablet in the article is provided by Takeda which has a $45B MCAP
Started: Kingalf, 21 Mar 2024 22:09
Last post: DSFLAT, 22 Mar 2024 06:41
Cash runway to 2026 is what they said during the investor presentation.
Dsflat - I was a little confused with your comment, the cash runway was previously end of 2024, how have you now got to 2026. Please correct me if I'm wrong but aren't they spending all the funds raised on the acquisition.
Started: CJ39, 9 Feb 2024 11:51
Last post: DSFLAT, 20 Mar 2024 14:00
Cash runway to 2026 is what the BOD stated today.
Perhaps this deal will persuade Stalicla to proceed in case Evgen find a better offer for SFX-]1.
Depending on whether the placing shares go into sticky hands we could see some steadying and uptrend if approved is gained at the AGM.
Exciting developments here in a niche market for unmet needs for neurological disorders and disease but it is seems long journey to commercialisation unless there is Big Pharma involvement to expedite urgent treatment for long suffering patients
Thanks, Trickymatters, but have not dumped the rump holding yet.
New tax year, unless some magic happens before then, lol.
We have seen some token inside buying, but really nowhere near enough IMO to make participation an attractive proposition. GLA.
FYI the Firefly merger with Wavedancer was approved by shareholders on the 18th which will give them a Nasdaq listing.
https://wavedancer.com/
For those wondering why I'm mentioning this, Stalicla announced that they were working with Firefly a year ago;
https://stalicla.com/media/news/firefly-neuroscience
DSFLAT….yep it’s good to go with your far fetched conspiracy theory.
Makes much more sense than the likely story that Stalicia has lost interest in SFX-01 and this non payment situation is a pre-cursor to them bailing out of the agreement with EVG.
Will be a double whammy for EVG if the agreement ceases and then management goes down the legal path with lawyers expenses to try and pursue them for damages. That would accelerate the cash burn with no assurance of a timely positive outcome.
Last post: Kingalf, 19 Mar 2024 22:17
You should all look on this as a positive, it could have been so much more and really diluted existing shareholders plus they can now say they have a 1 year runway. Let's just hope the bods finally contribute, it would be truly shocking if they again remained on the sidelines.
Started: CJ39, 15 Mar 2024 12:00
Last post: Mozax, 19 Mar 2024 09:18
Staclica lawyers would have requested phase 2 info removed from their website whilst the payment is under investigation.
My interpretation is that there is a new BoD at Staclica and everything is under review.
Radar,
The facts are facts..
An update on the dispute will be issued when Both parties Come to a conclusion.
WE don't know if the conclusion will be favorable or not for us , Evg shareholders ..
Meanwhile the market has priced in the risk .
Biotech investing demands patience and risk management so everyone to their own trades and convictions !
You can hope all you want until the cows come home or there are elephants in the sky.
Hope will not change the facts, son.
Well hopefully we will have an update soon about whether all is well with the Stalicla deal or not. I hope all is well, I want this to be successful, I want this to give us opportunities to make money from and that will end if the Stalicla deal collapses. I am invested here, only £1000 now at 1p but I’d be delighted to double up and it will pass 2.5p if Evgen get the $5.5m they are expecting.
There will always be people who will ignore the warnings and have total belief in a company, I’ve seen it so many times on these message boards. It’s dangerous to be like that though, you always need to be level headed and take into consideration both the positive and negatives.
You could ask why did the new CFO decide to join if things are in trouble. But you could also ask why did Axa sell their entire holding when they did? Why have the Directors never bought in?
This is like a poker hand, we don’t know how this will pan out yet, you can only piece together what we do know and then make an assumption on what will happen. The next update we have on this will be pivotal.
How many shares has he bought? How many shares have the other directors bought, since, say for example, the fall of the Roman Empire? Or has the window been closed all this time?
If something is brewing, I could not be more confident that it will be to the detriment of shareholders. Based on all the years I have been stuck in this dog!
Like so many outfits in this space, the stench makes Venice appear fragrant in a typical August.
Started: CJ39, 29 Feb 2024 13:50
Last post: radar, 1 Mar 2024 13:29
About 2 days but it will take about 10 years !
"To support these advancements, STALICLA will strengthen its Management Team and Board of Directors, reinforcing the foundation for the exciting journey ahead."
https://stalicla.com/media/news/stalicla-secures-$17.4million-in-series-b-round
My guess is that the Evgen contract will be revisited by the 'new' and more capable BOD and management and payment amounts reduced in value but staggered to allow continuation without draining Stalicla's funds too much...
Only a guess of course, but until Stalicla release news of the new BOD's and management I suspect nothing will be concluded either way
Maybe next week, new month and time to have addressed the dispute and taken on the new staff...?
It’s three weeks tomorrow that the dispute was issued. I would think a response would be imminent now. If Stalicla feel that Evgen have not met the requirements for the milestone payment they surely have these details to advise Evgen. If Evgen have met the requirements it should be quite obvious that they have done. I don’t see why this would take more than 3 weeks maximum.
I am optimistic that Evgen have met their requirements to get this $500k, I don’t personally see how they can’t have met the requirements.
A positive outcome to the dispute will see the share price rise towards 2p.
Started: DSFLAT, 28 Feb 2024 08:19
Last post: DSFLAT, 28 Feb 2024 10:16
No change to the Stalicla website regards SFX-01
https://stalicla.com/pipeline
STP2
STP2, or SFX-01, is a stabilized synthetic form of sulforaphane for which STALICLA has acquired the rights for neurodevelopment disorders worldwide from Evgen Pharma in October 2022.
STP2 is being advanced as a precision medicine treatment candidate for a subgroup of patients with ASD called Phenotype 2. Phase 1 data is currently being evaluated to support further clinical development into phase 2 trials.
One reality is that Stalicla still have SFX-01 on their website...
Amateurs alway expect good things winners resspect reality.
There’s a huge difference !
Yes the news regarding the dispute is significant. What are people anticipating with the response by Stalicla? You’d like to think news will come soon, it’s surely fairly straightforward, if Stalicla don’t believe conditions have been met they can surely advise what they are. I’m expecting a positive outcome, the board seem confident they have done everything asked of them many months ago.
Obviously positive news from Stalicla would be a bonus..
"The Company anticipates publication of the radio-sensitisation data for SFX-01 in models of rhabdomyosarcoma from collaborator La Sapienza University, Rome in early 2024."
The radio-sensitisation data should be interesting and we might see Huw do the media rounds when this is released.
Started: Tobethebest, 27 Feb 2024 14:40
Last post: Tobethebest, 27 Feb 2024 14:40
Can’t seem to get a live price for this share HL stuck on 1.p
Not moved all day .
Need this RNS to be published as only showing up on this board
In vivo results are encouraging looking forward to the published data
Fabulous news
Started: ba24ee, 27 Feb 2024 08:59
Last post: Tobethebest, 27 Feb 2024 10:06
Think this is the problem spread 0.20 now !
Let’s hope this afternoon does better
Hold for now
Gla
Spread to big.18%.put investors off
Started: ria20, 27 Feb 2024 08:27
Last post: DSFLAT, 27 Feb 2024 08:38
Holders don't want to attract any more trolls so keep quiet...
If I bought any more I'd have to issue a TR1 ;-)
Just need news of the Stalicla payment and progress and this goes off like a rocket
Cancer treatment= take this SFX-01 pill, get some radiotherapy and you should be all clear in a month' that's the best outcome for everyone
Ok thanks 🙏
Good luck I am in lol
News just getting out Tobethebest.....watch when the herd come....now climbing up the leaderboard in the top 10 now
Why so little interest on the board if this is going to fly?
Where are the big guns?
Trades seem small
Now on the leaderboard.....looking very strong and buying pressure very strong